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AbstrACt
Introduction There is a significant treatment gap, with 
only a few community- based services for people with 
schizophrenia in low- income and middle- income countries. 
Poor treatment adherence in schizophrenia is associated 
with poorer health outcomes, suicide attempts and death. We 
previously reported the effectiveness of supervised treatment 
in outpatients for schizophrenia (STOPS) for improving 
treatment adherence in patients with schizophrenia. 
However, STOPS was evaluated in a tertiary care setting 
with no primary care involvement, limiting its generalisability 
to the wider at- risk population. We aim to evaluate the 
effectiveness of STOPS+ in scaling up the primary care 
treatment of schizophrenia to a real- world setting.
Methods and analysis The effectiveness of the STOPS+ 
intervention in improving the level of functioning and 
medication adherence in patients with schizophrenia in 
Pakistan will be evaluated using a cluster randomised 
controlled trial design. We aim to recruit 526 participants 
from 24 primary healthcare centres randomly allocated in 
1:1 ratio to STOPS+ intervention and enhanced treatment 
as usual arms. Participants will be followed- up for 12 
months postrecruitment. The sample size is estimated for 
two outcomes (1) the primary clinical outcome is level of 
functioning, measured using the Global Assessment of 
Functioning scale and (2) the primary process outcome 
is adherence to treatment regimen measured using a 
validated measure. An intention- to- treat approach will be 
used for the primary analysis.
Ethics and dissemination Ethical approval has been 
obtained from Keele University Ethical Review Panel (ref: 
MH-190017) and Khyber Medical University Ethical Review 
Board (ref: DIR- KMU- EB/ST/000648). The results of the 
STOPS+ trial will be reported in peer- reviewed journals 
and academic conferences and disseminated to local 
stakeholders and policymakers.
trial registration number ISRCTN93243890.
IntroduCtIon
Schizophrenia is one of the leading causes 
of years lived with disability, especially in 
low- income and middle- income countries 
(LMICs).1 Existing evidence- based interven-
tions for schizophrenia have been poorly 
implemented and most LMICs have large 
treatment gap for schizophrenia.2 The treat-
ment gap represents the disparity between the 
strengths and limitations of this study
 ► This study aims to evaluate an approach that can 
be used for scaling up treatment for schizophrenia 
in resource poor settings and specifically addresses 
the gap in schizophrenia treatment.
 ► To the best of our knowledge, this is first study that 
uses a directly observed treatment short- course ap-
proach translated from an infectious disorder, that 
is, tuberculosis to a non- communicable disorder for 
scaling up the treatment for schizophrenia.
 ► The intervention involves primary care in treatment 
of schizophrenia in community, which is rarely done 
in low- income and middle- income country.
 ► The trial is powered two primary outcomes (1) a 
clinical outcome measure—Global Assessment of 
Functioning and (2) a process outcome measure—
adherence to medication.
 ► The measurement of treatment adherence is based 
on a subjective measure, that is, reporting from 
patients and carers that cannot be objectively 
validated.
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true prevalence of a disorder and the treated proportion 
of individuals diagnosed.3 Pakistan has one of the largest 
treatment gaps for schizophrenia, at an estimated 96%, 
this is contrast to an estimated median of 32.2% globally 
and 69% in LMICs.4 5 This treatment gap is attributed to 
a number of factors including poor treatment adherence 
with average non- treatment adherence rates of about 50% 
in schizophrenia,4 level of disability, a lack of primary care 
involvement and little to no access to treatment.5 This is a 
particularly important factor in rural areas, where health-
care resources are often diminished in comparison to urban 
centres.6 While the cost of antipsychotic medication in Paki-
stan is relatively low, economic and logistical factors remain 
significant barriers to medication access7 and the purchase 
of antipsychotic medication is often at the expense of other 
forms of essential out- of- pocket healthcare or even food.8
Reducing the treatment gap for schizophrenia in LMICs 
is critical. Medication non- adherence in patients with 
schizophrenia is associated with 2.8 times increased risk 
in hospital admission.9 The risk of death in patients who 
receive even minimal treatment is significantly reduced 
compared with patients receiving no treatment at all.10 
Furthermore, untreated psychosis can at least double 
the costs of managing chronic comorbid physical health 
conditions, leading to an increased stress on an already 
overburdened healthcare system.11
We previously reported a randomised controlled trial 
(RCT) of supervised treatment in outpatients for schizo-
phrenia (STOPS) in Peshawar, Pakistan.12 STOPS was 
developed using the Medical Research Council frame-
work for complex interventions13 and was modelled on 
the directly observed treatment short- course (DOTS) 
intervention to improve treatment adherence for people 
with tuberculosis (TB). The DOTS approach involves a 
TB worker or a family member directly supervising the 
patient taking all medication and recording this.14 DOTS 
is one of the most successful public health interven-
tions and has been shown to be as highly effective in the 
community as it is in specialist clinics, which in addition to 
its accessibility and low cost, which make it a highly appro-
priate intervention model for LMICs. Using the similar 
approach, STOPS intervention involved a family member 
of a person with schizophrenia observing and recording 
that medication had been taken. The family member is 
trained for this purpose. A previous evaluation of STOPS 
in a tertiary care setting showed that the STOPS signifi-
cantly improved treatment adherence and functioning as 
well reducing patient symptoms.11
The original STOPS intervention was evaluated in 
a tertiary care setting by mental health professionals, 
with no primary care involvement, limiting its scaling 
up and generalisability. Through a programme of qual-
itative work with key stakeholders in Pakistan, including 
patients, carers, healthcare professionals, researchers 
and local traditional healers, we adapted the STOPS 
model to STOPS+ with the aim of scaling up the inter-
vention and involving primary care in the management 
of schizophrenia.
Here, we outline the protocol for evaluating the 
STOPS+ in a real- world setting using a cluster RCT design.
MEthods And AnAlysIs
objectives
Primary objective
The primary objective is to evaluate the clinical effective-
ness of the STOPS+ intervention in improving medication 
adherence and functioning in patients with schizophrenia 
compared with enhanced treatment as usual (ETAU) in 
primary care in Pakistan.
Secondary objectives
1. To evaluate the cost- effectiveness of the STOPS+ inter-
vention compared with ETAU.
2. To assess the effectiveness of STOPS+ in reducing fami-
ly/caregiver burden and stigma in the community.
3. To evaluate whether STOPS+ leads to physical health 
improvement in patients with schizophrenia.
4. To investigate the implementation of STOPS+ in a pri-
mary care setting and the acceptability of STOPS+ for 
service users and healthcare providers, assessing the 
impact of STOPS+ in the wider healthcare system.
study setting
The intervention will be implemented and evaluated in 
the Peshawar district of Khyber Pakhtunkhwa (KP). KP 
is one of four provinces in Pakistan located in the North 
West region with an estimated population of 20.7 million. 
Health expenditure in Pakistan is about 1% of the gross 
domestic product with no separate provision for mental 
health services. The primary healthcare (PHC) facilities 
in KP are provided by a network of basic health units, civil 
dispensaries and rural health centres. Typically, each PHC 
facility consists of a primary care physician, a multipur-
pose PHC technician (MT) and a female health worker.15 
Training PHC providers to manage mental health condi-
tions and the incorporation of mental health services into 
primary care are both envisaged in the current health 
policy but have not yet been fully realised.5
trial design
A cluster RCT will be used to investigate the efficacy of 
the STOPS+ intervention compared with ETAU in people 
living with schizophrenia. The cluster RCT design will 
help to evaluate the implementation of STOPS+ at the 
healthcare facility level and to minimise the contamina-
tion of intervention and control arms.
the control: EtAu
Typically, in Pakistan, treatment for schizophrenia consists 
of accessing hospital- based psychiatric services with little 
to no involvement of PHC and a limited provision of 
medication from the hospital pharmacy. ETAU provided 
in the control clusters will include the treatment received 
by patients’ routine healthcare setting, which includes 
treatment provided by a psychiatrist in the outpatient 
clinics of the psychiatry department of the local hospital 
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and brief counselling about the treatment and outcome 
of the disorder. Patients may be admitted to an inpatient 
unit at the hospital. This will be enhanced in the control 
cluster PHCs with training provided to PHC physicians in 
WHO Mental Health Gap Action Programme (MhGAP) 
(https://www. who. int/ mental_ health/ mhgap/ en/ t) in 
addition to the regular and reliable provision of psycho-
tropic drugs at the PHC. The patients will be informed 
that the antipsychotic medication is available in the PHC 
centre and they can access the centre for supply of medi-
cation. The PHC physician will have the option to liaise 
with the treating psychiatrist, as provided in the MhGAP 
guidelines.
stoPs+ intervention
The STOPS+ intervention will consist of the ETAU plus 
the following components.
Supervision by a trained family member for dispensing and 
administering medication
A family member who is living with the patient for a 
minimum of 6 months prior to recruitment to the trial 
will be nominated by the patient. The family member 
will dispense medication, observe that is has been taken 
correctly and record this information on a simple sheet 
of paper designed and used in the previous STOPS 
trial.9 Family members will be reminded to administer 
the medication by an automated text message system, 
which will also request a response once the medication 
has been taken correctly. The text message reminders will 
be sent everyday for the first 3 months after starting the 
treatment. If the family member does not have access to 
a mobile phone, a handset and training in using it will be 
provided.
A multipurpose technician (MPT) from each PHC 
centre will provide training to family members for the 
storage and administration of the medication, recording 
when the medication has been taken correctly and the 
importance of maintaining the family dynamic.
Treatment for schizophrenia at PHC level supervised by mental 
health professionals
Ongoing management and monitoring of the patient’s 
schizophrenia will take place at their PHC centre by the 
PHC physician, under the supervision of the treating 
psychiatrist with the help of the mobile technology 
platform smartphone for monitoring, assessment and 
remote treatment (SMART). SMART will provide two- 
way communication between mental healthcare profes-
sionals. One month’s supply of medication will be made 
available, via their PHC, to the family member. The 
automated messaging system will also remind the family 
member about collecting the following month’s supply.
Monitoring the availability of essential psychotropic medication 
and their side effects
A kit to monitor the supply of medication will be used 
to monitor the availability and supply of psychotropic 
medication. This will consist of (a) a cupboard dedicated 
specifically for the storage of psychotropic medication, 
(b) a tracking sheet used to monitor the stock levels 
and (c) a simple checklist for monitoring side effects of 
antipsychotics.
Assessment of barriers and facilitators of implementation of 
the intervention
The use of theory to inform the development of behaviour 
change interventions is strongly advocated by experts in 
the field. We have designed the process of implementa-
tion using theory developed for implementation and 
tested previously in UK Primary Care Practice.16 17 We will 
evaluate the barriers and facilitators to implementation 
of the intervention using qualitative methods. We will 
hold at least four focus groups (with patients and carers, 
MPTs, traditional and faith healers and primary care clini-
cians) in which we will explore the barrier and facilita-
tors to supervising the treatment of schizophrenia in the 
community, modification of the STOPS programme to 
STOPS+ for use in the community and the present status 
of schizophrenia care in the community
Patient and public involvement
STOPS+ is underpinned by culturally appropriate and 
context- bespoke patient and public community engage-
ment and involvement at every stage of the project (inter-
vention development, RCT and process evaluation). The 
STOPS+ intervention will be refined with input from the 
key stakeholder groups including patients, carers, health 
professionals, local councillors, community leaders such 
as religious leaders and community experts and policy-
makers. Small group meetings using local Jirgas (Jirga is 
traditional, local participatory and decision- making body 
which is well established in Pathan culture and brings 
together local tribal, ethnic and religious leaders) will 
help in community engagement.
Primary outcome measure
In view of the pragmatic nature of the trial, we will use two 
distinct primary outcomes:
1. The primary clinical outcome will be the level of func-
tioning, measured using the Global Assessment of 
Functioning (GAF) scale.18 GAF is a commonly used 
tool in schizophrenia, particularly for the pragmatic 
trials.19
2. The primary process outcome will be adherence to 
treatment regimen. The adherence to treatment will 
be measured using a questionnaire adapted from Herz 
et al.20 This measure for assessing treatment adherence 
was successfully used in our previous STOPS study.9
secondary outcomes
The details of secondary outcomes and the standardised 
instruments for measuring these are given in table 1. 
These instruments will measure secondary outcomes such 
as physical health outcomes, family/caregivers burden 
and internalised stigma.
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Table 1 Description of outcome measures and instruments
Domains measured Measure
Sociodemographics Age
Gender
Years in education
Marital status
Work status
Mini- Neuropsychiatric Interview 
for diagnosis of schizophrenia21
Physical health Body mass index
Blood pressure
Waist circumference
Primary outcomes
  Level of functioning Global Assessment of 
Functioning18
  Level of adherence Treatment adherence rating 
scale20
Secondary outcomes
  Mental state and 
psychiatric symptoms
Brief Psychiatric Rating Scale40
  Caregivers’ burden Family Burden Scale41
  Perceived stigma Internalised Stigma of Mental 
Illness42
  Side effects of 
antipsychotic medication
Glasgow Antipsychotic Side- 
Effects Scale43
  Cost of care Client Service Receipt 
Inventory44
  Quality of life and cost- 
effectiveness
EuroQol (EQ5D)45
  Illness severity, 
improvement and 
response to treatment
Clinical Global Impression 
Scale46
  Drug use DAST Drug Screening Tool47
  Depression Patient Health Questionnaire48
  Suicide Ideation Suicide Behaviours 
Questionnaire Revised49
DAST, Drug Abuse Screening Test; EQ5D, EuroQol 5 Dimension.
Eligibility criteria
Patients will be eligible for inclusion if they
a. Have a diagnosis of schizophrenia (F20.9) or schizoaf-
fective disorder (F25.9) based on the International 
Classification of Disease 10 criteria assessed using the 
Mini- International Neuropsychiatric Interview.21
b. Are aged between 17 and 65 years.
c. Do not meet the criteria for remission as defined by 
the Remission in Schizophrenia Working Group.22
d. Have capacity and are able to give informed consent.
e. Have a family member who is also willing to participate 
in the trial and supervise the treatment after training 
by the research team.
Exclusion criteria will be kept to a minimum to ensure 
that the study can examine the real- world implementa-
tion of the STOPS+. The patients who can not partici-
pate in the study due to one of following reasons will be 
excluded (1) a serious or unstable medical illness, (2) 
evidence of learning disability, (3) severe drug depend-
ence requiring treatment and/or detoxification and (4) 
pregnant or breast- feeding.
duration of treatment and follow-up
Both groups will be followed up for 12 months after 
recruitment in the study. The follow- up using face- to- face 
assessments will be carried out by trained research assis-
tants in a health facility which is not part of participating 
PHCs to preserve the blindness of clusters. All of the 
outcomes will be measured at baseline, at 6 months and 
at 12 months by research assistants.
Participant identification
Participants will be identified from two possible sources 
(1) patients living in the area of the participating PHCs 
and presenting at psychiatry outpatient services of the 
hospitals in the area and (2) potentially eligible patients 
identified by the PHC workers during community 
engagement or attending the PHCs. Eligible participants 
will be informed about the trial orally by the PHC staff 
and written information will be provided in the local 
language (Urdu). Those interested in taking part will be 
asked to give written informed consent. For participants 
who cannot read and write, witnessed oral consent and a 
thumbprint in lieu of a signature will be used. The witness 
will not be a member of the research team. The proce-
dure has been used in our previous trials in the area.23
randomisation and allocation concealment
Randomisation will occur at the PHC level, where PHCs 
will be allocated at a ratio of 1:1 to either deliver the 
STOPS+ intervention or ETAU. Twenty- four PHCs will be 
recruited to the study, 12 will be randomised to deliver 
ETAU and 12 will be randomised to deliver the STOPS+ 
programme. PHC randomisation will be stratified by 
urban/rural setting. Randomisation will be carried out 
by an independent statistician at the Khyber Medical 
University (KMU), Peshawar by using a remote computer- 
generated random sequence. Randomisation and will 
be based on the list of primary care centres in Peshawar, 
provided by the health department of KP. The urban/rural 
classification is determined as per the Peshawar district 
council. It is not possible to blind study participants from 
their treatment arm allocation. However, the assessment 
team that conducts the baseline and follow- up assessments 
(6 and 12 months) will be masked to the treatment arm 
of the cluster. The outcome measures will be adminis-
tered by trained research assessment teams (outcome 
assessors), who are independent of the intervention team 
and the team involved in consenting and screening. The 
outcome assessment will not be carried out at any partic-
ipating PHC. The assessment teams will be told that they 
 o
n
 July 3, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034709 on 30 June 2020. Downloaded from 
5Shepherd TA, et al. BMJ Open 2020;10:e034709. doi:10.1136/bmjopen-2019-034709
Open access
are evaluating two interventions and that there is genuine 
equipoise about which one is better. Study participants will 
be instructed to not discuss the PHC they are attending 
or the treatment details. During all assessments, the 
primary outcome measures (treatment adherence scale 
and GAF) will be completed first to minimise the risk of 
bias in the event of unmasking and, if it occurs, the point 
of unmasking will be recorded. Sensitivity analyses will 
be carried out to assess the effect of unmasking on the 
primary outcomes. The data linking each PHC with treat-
ment allocation status is kept separate from the outcome 
dataset until the time of the final analysis. The trial statisti-
cian will be blind to allocation status.
screening, data collection and follow-up
After identification of potentially eligible patients, they 
will first be orally informed about the trial by one of 
the health workers in the local Pushto language (MT 
in the community or a health professional in one of the 
health facilities mentioned above). They will be asked 
whether they agree that a member of the research team 
will provide them with further information about the 
research. If permission is given, a research assistant will 
meet with the patient and will request informed consent. 
The informed consent for participation in the study will 
be taken within 1 week of the first contact. Participants will 
be free to decline to participate or withdraw at any time 
without their routine healthcare being affected. Before 
taking part in any interviews, oral and written informa-
tion about the study and its purpose will be provided to 
respondents in the local language.
After obtaining informed consent, the research assis-
tant will decide whether the patient meets the inclusion 
criteria and have a family member who is willing to super-
vise the treatment as specified in the STOPS+ procedures. 
If the patient is not eligible from the screening assess-
ment, the reason for ineligibility will be explained to the 
patient and they will be signposted for further advice and 
to continue to receive treatment at their routine health 
facility. Eligible patients will be provided with a further 
participant information sheet about the trial. Addition-
ally, for those in the intervention arm, the nominated 
relative will receive a participant information sheet about 
the trial and about the tasks required in supervising the 
treatment If nominated family member is available with 
the patient, this information will be provided at the same 
time. If the family member is not available, patients and 
the family member will be asked to visit the health facility 
again within 1 week. The patient and the relative will each 
be given the opportunity to ask any questions about the 
trial. The information sheets are provided in Urdu. For 
illiterate patients, the research assistants will explain the 
same information in local Pushto language or in Urdu. 
Following the informed consent, the baseline data will be 
collected.
sample size calculation
A mean difference of 6 on the primary clinical outcome 
measure (GAF) with a pooled study SD of 15 was observed 
in our previous trial in the same setting.12 A recent indi-
cated minimum clinically important difference for the 
GAF in schizophrenia patients has been given as a mean 
difference of 4.24 A total sample size of 526, that is, 263 
patients in each arm (recruited across 24 PHCs, with an 
average cluster size of 22 patients) has over 90% power 
to detect a mean difference of 6 and 85%–90% power to 
detect a more modest mean difference of 4 in the GAF 
given a two- tailed significance level of 0.05 and based on 
the following parameter assumptions: (1) baseline–out-
come correlation of 0.5, repeated measures correlation of 
0.725 and loss to follow- up of 20% (patient- level parame-
ters) and (2) intracluster correlation coefficient of 0.0126 
and coefficient of variation in cluster sizes of 0.65 (PHC- 
level parameters).27 The primary endpoint for the GAF is 
the ‘average’ GAF across 6 and 12 months follow- up.
This sample size has 90% power to detect at least a 
20% absolute difference in the treatment adherence rate 
between the intervention arm compared with the ETAU 
arm at 6 and/or 12 months follow- up based on two- tailed 
alpha of 0.025 (to account for multiple testing in respect 
of 6- month and 12- month testing). This is based on an 
observed ≈20% higher level of adherence within the 
intervention compared with ETAU arms in the original 
STOPS trial at 3 and 12 months follow- up,11 and further 
assuming the design effect PHC- level parameters as noted 
in (2) above. Thus, the study is adequately powered to 
detect significant differences (at the level of two- tailed 
alpha of 0.05 in each case) across the two distinct primary 
outcomes: (1) the primary clinical outcome (GAF) and (2) 
the primary process outcome (medication adherence).
trial management and monitoring
The STOPS+ trial will be monitored in line with the 
protocol and the trial standard operating procedures. An 
independent Trial Steering Committee (TSC) which will 
have service user representatives will monitor trial prog-
ress. The TSC is empowered to independently review the 
ethical and data management procedures. A Data and 
Safety Monitoring Board (DSMB) will be convened to 
ensure the safety of participants and the integrity of the 
data. The PHCs in the trial will receive training around 
safety reporting and additionally, participants and their 
family members will be informed of how to report 
concerns and safety issues, while they are participating 
in the trial. The Project Management Committee will be 
responsible for setting up the trial, ongoing management 
and monitoring, promotion of the study, training and the 
interpretation of the results.
safety and adverse events reporting
All adverse events and serious adverse events (SAEs) that 
are reported by the participant, family member or iden-
tified by the trial team or PHC staff members during the 
trial will be recorded and reported following trial safety 
reporting procedures. Related and unexpected SAEs 
will be reported to the local Research Ethics Committee, 
DSMB and TSC within 15 days. The DSMB will review all 
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safety data and make any decisions regarding early termi-
nation of the study in line with their respective terms of 
reference.
data management
All data will be managed in line with the protocol and 
will be stored securely following the KMU and Keele 
University standard policy on data storage and confiden-
tiality. Individual participant data will be pseudonymised 
through the use of a unique study ID and will be stored 
securely and separately from any identifiable data. Access 
to data will be restricted to members of the research team. 
Outcome data will be entered into an electronic database 
which will be stored on an encrypted secure network at 
KMU requiring a password to access. Data entry will be 
quality checked and coded using standard processes.
statistical analysis
Statistical analysis will be performed blind to cluster allo-
cation. Primary analysis will be on an intention- to- treat 
(ITT) basis, with all participants analysed in their cluster. 
Between- group differences for both primary outcome 
measures (GAF and medication adherence) will be anal-
ysed using longitudinal mixed models that accommodate 
clustering at the (upper/hierarchical) practice level as 
well as repeated outcome measurements across three 
time points (baseline, 6 and 12 months) per participant, 
that is, linear/logistic mixed models for numerical and 
categorical outcomes, respectively, including PHC and 
participant as random factors. These models will be used 
to quantify the absolute between group difference in the 
primary clinical outcome (GAF) and odds ratio (and 
extracted absolute difference) for the primary process 
outcome (% adherence)—using linear and logistic 
models, respectively. For the GAF, the primary endpoint 
is the ‘average’ GAF over 6 and 12 months using available 
and modelled data to estimate the combined summary 
average mean difference in GAF between treatment arms 
over the 6- month and 12- month timeline; statistical signif-
icance in this case being given against two- tailed p=0.05. 
Though the ‘average’ is the single primary endpoint for 
the GAF, we will also evaluate the treatment- by- time inter-
action to give estimates of between- arm mean differences 
at the individual 6 and 12 months follow- up time points 
(secondary endpoints).
For medication adherence, between- group comparison 
at both 6 and 12 months is primary (derived through 
treatment- by- time interaction within the generalised 
mixed model)—hence, the requirement to take into 
account the multiple testing by assessing significance 
against a more conservative two- tailed p=0.025. Esti-
mates of between- group mean differences will be given 
including 95% CIs and p values. The mixed models 
(detailed above) will be adjusted for age, gender, base-
line GAF score and corresponding baseline score of 
the outcome being measured as individual- patient- level 
covariates, PHC- level characteristics (PHC size), stratifica-
tion variable (rural/urban) and a random effect for the 
PHC. Mixed- model analysis fulfils the ITT principle with 
missing data being accounted for under the missing at 
random assumption.
Cost-effectiveness
The cost of STOPS+ will be evaluated against ETAU using 
the Service Receipt Inventory,28 which has been used in 
previous trials in Pakistan.21 This will include the cost of 
primary and outpatient care visits, inpatient admissions, 
drug regimens, diagnostic tests, travel time, transport 
costs and lost days from work. Costs will be subsequently 
linked to outcomes in order to establish whether STOPS+ 
represents a cost- effective use of resources (eg, whether 
the additional cost of supervision by the relative are offset 
by the reduced hospital care and/or improvements in 
the clinical outcome—GAF and Quality Adjusted Life 
Years (QALY). Cost- effectiveness planes and acceptability 
curves will evaluate the uncertainty in estimates as well 
as the probability of STOPS+ being cost- effective across a 
range of willingness- to- pay thresholds. Adjusted analysis 
will be carried to accommodate clustering of PHCs.
EthICs And dIssEMInAtIon
Ethical approval to conduct this trial has been obtained 
from Keele University Ethical Review Panel (reference: 
MH-190017) and Khyber Medical University Ethical 
Review Board (ref: DIR- KMU- EB/ST/000648). Subse-
quently, recruitment began on 1 November 2019. Results 
will be disseminated through peer- reviewed journals 
and academic conferences. The trial is being conducted 
in accordance with the International Conference on 
Harmonisation/Good Clinical Practice Guidelines 
(1996) which are consistent with principles of Declara-
tion of Helsinki (1996) Ethical Principles for Medical 
Research Involving Human Subjects.
Process evaluation
Patients and relatives, primary care physicians and MPT 
from participating PHCs in both arms will be invited to 
take part in a semistructured interview to assess the accept-
ability of intervention and its implementation in the 
health system.29 These interviews will last approximately 
30–40 min and will be audio recorded with permission. 
A minimum of 20 individual semistructured interviews30 
will be conducted (continuing until data saturation is 
reached)31 32 with patients and their relatives to explore 
(a) the acceptability of the STOPS +intervention, (b) 
the experience/burden of the training and support for 
the patient’s family member and (c) barriers and facil-
itators to medication adherence and overall satisfaction 
with the intervention and trial participation. A minimum 
of 10 interviews will be conducted with PHC physicians. 
In addition, we will conduct interviews with at least five 
decision- makers with responsibilities for developing or 
implementing health policy in the directorate of health 
in order to capture their perceptions about the feasibility, 
the benefits, challenges and acceptability of STOPS+ 
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in the health system. Participants for these interviews will 
be purposively sampled to stratify by gender and urban/
rural setting. A semistructured topic guide will be used to 
facilitate interviews. Informed consent will be obtained 
prior to the start of the interview and will include consent 
for the use of direct pseudonymised quotes.
An inductive, exploratory framework will be adopted 
using thematic analysis based on the principles of 
grounded theory.33 34 A sample of early transcripts will 
be independently coded by the research team and a 
coding framework agreed on. This framework will then 
be applied to subsequent coding. Coded data will be anal-
ysed independently by qualitative study leads at Keele and 
KMU to develop categories and themes to be discussed 
in wider research team meetings. Constant comparison 
will be used to explore connections within and across 
transcripts and codes, highlighting consistencies and 
variation.35 Analysis will follow an iterative process, with 
emergent findings used to further refine topic guides for 
subsequent interviews.
dIsCussIon
People suffering from schizophrenia represent one of 
the most disadvantaged groups in LMICs facing a wide 
mental health treatment gap. A number of psychosocial 
interventions have been evaluated in RCTs and there is 
consensus that the treatment of schizophrenia should 
combine antipsychotic medication and psychosocial 
interventions.36 However, there is limited evidence how 
these interventions can be implemented in the real- world 
settings.
The proposed study adopts an implementation 
approach addressing systemic barriers to reduce treat-
ment gap for schizophrenia in the community. The 
STOPS+ intervention aims to address three major 
implementation barriers (1) improving supply of anti-
psychotic medication at primary care level, (2) involving 
primary care workers in the treatment of schizophrenia 
and (3) improving treatment adherence by involving 
family members in supervising treatment. The STOPS+ 
approach therefore goes beyond most psychosocial 
interventions evaluated in the treatment of schizo-
phrenia in LMICs37 38 in addressing the health system, 
community and service users- related factors to improve 
access to treatment.
A unique aspect of the trial is that it is powered for 
both process and clinical outcomes. These two primary 
outcomes are (1) a clinical outcome measure—GAF and 
(2) a process outcome measure—adherence to medica-
tion. This combined with a process evaluation carried out 
after completion of the cluster RCT will provide much 
needed evidence on the implementation of community- 
based interventions for schizophrenia in LMICs settings. 
The WHO Mental Health Action Plan (2013–2020) 
requires that there is an absolute increase of 20% in 
service coverage for severe mental disorders.38 The 
results of the trial may help to understand the processes 
and implementation strategies to achieve that goal and 
could provide an effective public health intervention for 
schizophrenia.39
A major strength of the STOPS intervention is that it 
is based on an infectious disease model that has been 
successfully used in improving treatment adherence for 
TB, that is, DOTS (http://www. searo. who. int/ tb/ topics/ 
what_ dots/ en/) as a public health intervention. The 
DOTS model is currently being used in most LMICs, 
including the settings of this trial. This can potentially 
help in integration of the care for a non- communicable 
chronic disorder like schizophrenia in the public health 
systems of LMICs.
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